China smartphone shipments slumped in June on inventory overhang: Jefferies
Paul Blanchfield, President of Lantheus Holdings, Inc. (NASDAQ:LNTH), a $7.3 billion medical diagnostics company showing impressive momentum with a 60% return over the past year, recently sold 2,084 shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. The shares were sold at an average price of $98.00 each, generating a total of $204,232. Following this transaction, Blanchfield retains 91,828 shares in the company. According to InvestingPro analysis, the stock appears slightly undervalued at current levels.
In addition to the sale, Blanchfield acquired 26,871 shares through a combination of restricted stock units and performance-based restricted stock units. These acquisitions were made at no cost and are part of a compensation package that includes vesting over a three-year period. The performance-based units are contingent on achieving certain shareholder return metrics, potentially adjusting the final award size based on performance outcomes. InvestingPro data shows the company maintains an excellent financial health score, with 12 additional key insights available to subscribers.
Blanchfield also received stock options for 15,668 shares, exercisable at $100.48 per share, which will vest in equal installments over three years starting in March 2026. These moves are part of a pre-established trading plan under Rule 10b5-1, which allows executives to schedule trades in advance to avoid potential conflicts of interest. The company’s strong financial position is reflected in its ability to maintain healthy cash flows and operate with moderate debt levels.
In other recent news, Lantheus Holdings reported its fourth-quarter 2024 earnings, which surpassed analyst expectations. The company achieved earnings per share (EPS) of $1.59, exceeding the forecast of $1.55, and revenue of $391.1 million, surpassing the expected $377.24 million. This positive performance was driven by strong sales from its flagship product, Polarify, contributing significantly to revenue growth. Lantheus forecasts 2025 revenue between $1.545 billion and $1.610 billion, indicating potential growth of 1-5%. Mizuho (NYSE:MFG) Securities recently adjusted its price target for Lantheus, reducing it from $150 to $140, while maintaining an Outperform rating. This adjustment followed Lantheus’ earnings report, which showed robust performance, particularly from its DEFINITY franchise. The company’s financial guidance for 2025 currently excludes potential impacts from pending acquisitions of Life Molecular Imaging and Evergreen Medical (TASE:BLWV) Services. Analysts from Mizuho expressed confidence in Lantheus’ ability to navigate market challenges and achieve its commercial targets, particularly with its product PYLARIFY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.